Abstract:Background Biliary atresia (BA) is the most common serious neonatal biliary disease, characterized by progressive biliary inflammation and fibrosis. We aim to comprehensively and systematically investigate the complex pathological process of BA from multiple molecular dimensions, combining transcriptomics, proteomics, metabolomics, and single-cell RNA sequencing. Methods Transcriptomic, proteomic, and metabolomic techniques were utilized for detecting and integrating the molecular characteristics of BA liver tissues. By combining single-cell RNA sequencing data, we were able to pinpoint the immune cells regulated by the abnormal metabolite in BA. In vitro experiments were detected to reveal the role and mechanism of the abnormal metabolite signaling pathway in the progression of BA. In vivo, the effect of inhibiting abnormal signaling pathway on alleviating bile duct injury and fibrosis was verified in the rotavirus type A (RRV) induced mouse model. Results We found the aberrant regulation and activation of the sphingolipid metabolism pathway was observed in BA by transcriptomic, proteomic, and metabolomic data analysis. By integrating BA single-cell RNA sequencing data, we found that Sphingosine-1-Phosphate Receptor 4 (S1PR4), a receptor of Sphingosine-1-Phosphate signaling, was primarily expressed in CX3CR1+CD8+ effector T (Teff) cells. In vitro experiments demonstrated that S1P promoted the migration of CX3CR1+CD8+Teff cells, and S1P/S1PR4 signaling facilitated the differentiation of CX3CR1+CD8+Teff cells into CD8+ tissue-resident memory T (TRM) cells. Co-culture of CD8+TRM cells could induce apoptosis of cholangiocytes. In the RRV mouse model, S1PR4 inhibitor could alleviate liver inflammation and fibrosis by inhibiting the accumulation of CD8+TRM cells (IDDF2024-ABS-0207 Figure 1. S1P S1PR4 promotes the differentiation of CD8 TRM cells aggravating bile duct injury in biliary atresia). Conclusions This study used multi-omics data integration to reveal aberrant regulation of the sphingolipid metabolism pathway in BA. The activated S1P/S1PR4 signaling pathway in BA liver recruited CX3CR1+CD8+Teff cells to accumulate around the cholangiocytes. S1P/S1PR4 signaling promoted the differentiation of CX3CR1+CD8+Teff cells into CD8+TRM cells, subsequently triggering apoptosis and injury of cholangiocytes, thus exacerbating the progression of BA. Targeting S1P/S1PR4 signaling activation is a promising therapeutic strategy for BA treatment.

Biliary atresia: insights into mechanisms using a toxic model of the disease including Wnt and Hippo signaling pathways and microtubules

Systems Analysis of Biliary Atresia Through Integration of High-Throughput Biological Data

The Aberrant Expression of HLA-DR in Intrahepatic Bile Ducts in Patients with Biliary Atresia: an Immunohistochemistry and Immune Electron Microscopy Study.

A novel model of injured liver ductal organoids to investigate cholangiocyte apoptosis with relevance to biliary atresia

Biliary Atresia: Clinical and Research Challenges for the Twenty-First Century

Advanced Therapies for Congenital Biliary Tract Malformation: from Bench to Bedside

Biliary atresia: the role of gut microbiome, and microbial metabolites

Integrative single-cell and spatial transcriptomic analyses identify a pathogenic cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia

YAP Activation and Implications in Patients and a Mouse Model of Biliary Atresia

Animal and organoid models to elucidate the anti-fibrotic effect of steroid on biliary atresia

IDDF2024-ABS-0207 S1P/S1PR4 Promotes the Differentiation of CD8+TRM Cells Aggravating Bile Duct Injury in Biliary Atresia

Environmental Toxin Biliatresone-Induced Biliary Atresia-like Abnormal Cilia and Bile Duct Cell Development of Human Liver Organoids

Mechanism of biliary atresia caused by T follicular helper cells-induced immune injury

Metabolic regulation of cholestatic liver injury by D-2-hydroxyglutarate with the modulation of hepatic microenvironment and the mammalian target of rapamycin signaling

Liver Immune Profiling Reveals Pathogenesis and Therapeutics for Biliary Atresia

Identifying and validating molecular subtypes of biliary atresia using multiple high-throughput data integration analysis

MAPK signaling pathway induced LOX-1+ polymorphonuclear myeloid-derived suppressor cells in biliary atresia

Current Understanding in the Clinical Characteristics and Molecular Mechanisms in Different Subtypes of Biliary Atresia

Identification of diagnostic biomarkers and potential therapeutic targets for biliary atresia via WGCNA and machine learning methods

MicroRNA-21/PTEN/Akt Axis in the Fibrogenesis of Biliary Atresia

Liver-restricted deletion of the biliary atresia candidate gene Pkd1l1 causes bile duct dysmorphogenesis and ciliopathy